These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 2979698)
1. The place of famotidine in anti-ulcer therapy. Mann SG Aliment Pharmacol Ther; 1987; 1 Suppl 1():504S-509S. PubMed ID: 2979698 [TBL] [Abstract][Full Text] [Related]
2. [Famotidine in the treatment of gastroduodenal ulcer]. Lengyel G; Fehér J Orv Hetil; 1994 Oct; 135(42):2299-304. PubMed ID: 7970643 [TBL] [Abstract][Full Text] [Related]
3. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Langtry HD; Grant SM; Goa KL Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505 [TBL] [Abstract][Full Text] [Related]
4. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. Campoli-Richards DM; Clissold SP Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864 [TBL] [Abstract][Full Text] [Related]
5. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Hudson N; Taha AS; Russell RI; Trye P; Cottrell J; Mann SG; Swanell AJ; Sturrock RD; Hawkey CJ Gastroenterology; 1997 Jun; 112(6):1817-22. PubMed ID: 9178671 [TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of lecedil (famotidine) in the therapy of patients with peptic ulcer]. Grebenev AL; Sheptulin AA; Smakov GM; Kornienko AA; Trukhmanov AS Klin Med (Mosk); 1993; 71(6):30-2. PubMed ID: 8145499 [TBL] [Abstract][Full Text] [Related]
7. Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease. Thomson AB Hepatogastroenterology; 1990 Jul; 37 Suppl 1():18-28. PubMed ID: 1976583 [TBL] [Abstract][Full Text] [Related]
8. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Taha AS; McCloskey C; Prasad R; Bezlyak V Lancet; 2009 Jul; 374(9684):119-25. PubMed ID: 19577798 [TBL] [Abstract][Full Text] [Related]
9. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. Taha AS; Hudson N; Hawkey CJ; Swannell AJ; Trye PN; Cottrell J; Mann SG; Simon TJ; Sturrock RD; Russell RI N Engl J Med; 1996 May; 334(22):1435-9. PubMed ID: 8618582 [TBL] [Abstract][Full Text] [Related]
10. [Duodenal ulcer, study of gastric secretion and rational treatment with famotidine in different doses]. Santoro E; Morucci P; Idotta G; Scutari F Ann Gastroenterol Hepatol (Paris); 1989 Oct; 25(5):211-4. PubMed ID: 2817767 [TBL] [Abstract][Full Text] [Related]
11. Morning versus evening dose: a comparison of three H2-receptor blockers in duodenal ulcer healing. Khasawneh SM; Affarah HB Am J Gastroenterol; 1992 Sep; 87(9):1180-2. PubMed ID: 1519576 [TBL] [Abstract][Full Text] [Related]
13. Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer. Ohnishi K Hepatogastroenterology; 1990 Jul; 37 Suppl 1():6-10. PubMed ID: 2210613 [TBL] [Abstract][Full Text] [Related]
14. Comparison between single morning and bedtime doses of 40 mg famotidine for the treatment of duodenal ulcer. Marenco G; Menardo G; Pallini P; Rossini FP; Saggioro A Aliment Pharmacol Ther; 1989 Jun; 3(3):285-91. PubMed ID: 2520624 [TBL] [Abstract][Full Text] [Related]
15. Drug therapy of peptic ulcer disease. Ching CK; Lam SK Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483 [TBL] [Abstract][Full Text] [Related]
16. [Famotidine in the treatment of duodenal peptic ulcer]. Bussalleu A; Berrios J; Espejo H; Espinoza R; Farfán G; Galarza J; Guerra J; Nago A; Simich C; Valladares G Rev Gastroenterol Peru; 1990; 10(1):27-32. PubMed ID: 2129891 [TBL] [Abstract][Full Text] [Related]
17. The efficacy and tolerability of famotidine and ranitidine on the healing of active duodenal ulcer and during six-month maintenance treatment, with special reference to NSAID/aspirin-related ulcers. Bank S; Greenberg RE; Magier D; Lavin PT Clin Ther; 1991; 13(2):304-18. PubMed ID: 1863945 [TBL] [Abstract][Full Text] [Related]
18. Comparison of famotidine with cimetidine and ranitidine. Berardi RR; Tankanow RM; Nostrant TT Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559 [TBL] [Abstract][Full Text] [Related]
19. Central nervous system reactions associated with famotidine: report of five cases. Odeh M; Oliven A J Clin Gastroenterol; 1998 Oct; 27(3):253-4. PubMed ID: 9802455 [TBL] [Abstract][Full Text] [Related]
20. Stress ulceration in the intensive care unit: use of H2-receptor antagonists. Moore JG Aliment Pharmacol Ther; 1991; 5 Suppl 1():111-9. PubMed ID: 1679669 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]